Literature DB >> 15804174

Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier.

Zhengrong Cui1, Su-Ji Han, Dileep Padinjarae Vangasseri, Leaf Huang.   

Abstract

A novel and improved vaccine delivery system and/or adjuvant is actively sought to enhance the potency of vaccines. Previously, we reported that strong antitumor immunity could be generated when a peptide antigen was incorporated into LPD (cationic liposome-polycation-pDNA) nanoparticles. In this study, we found that both the cationic liposome and DNA are required for the full immunostimulation activity of LPD. The unique ability of LPD to readily move into local lymphoid tissues and to activate antigen-presenting cells might be responsible for its strong immunostimulatory activity. Moreover, cationic liposome stimulates the expression of CD80/CD86 on dendritic cells (DCs), but not the release of TNF-alpha from DCs, suggesting the existence of a NF-kappaB-independent immunostimulation pathway for cationic lipids such as DOTAP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804174     DOI: 10.1021/mp049907k

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  28 in total

1.  Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.

Authors:  Jia-Yu Liu; Tsaiyu Chiang; Chun-Hung Liu; Guann-Gen Chern; Ts-Ting Lin; Dong-Yu Gao; Yunching Chen
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

2.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.

Authors:  Xinran Li; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2010-12-21       Impact factor: 5.571

Review 3.  Liposome-nucleic acid immunotherapeutics.

Authors:  Steven Dow
Journal:  Expert Opin Drug Deliv       Date:  2008-01       Impact factor: 6.648

4.  Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.

Authors:  Yunching Chen; Joyeeta Sen; Surendar Reddy Bathula; Qi Yang; Raffaella Fittipaldi; Leaf Huang
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

5.  A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.

Authors:  Xiaojuan Yang; Yong Peng; Bo Yu; Jianhua Yu; Chenguang Zhou; Yicheng Mao; L James Lee; Robert J Lee
Journal:  Mol Pharm       Date:  2011-03-23       Impact factor: 4.939

Review 6.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 7.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

8.  Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens.

Authors:  Nijaporn Yanasarn; Brian R Sloat; Zhengrong Cui
Journal:  Mol Pharm       Date:  2011-06-07       Impact factor: 4.939

9.  Antitumor activity of G3139 lipid nanoparticles (LNPs).

Authors:  Xiaogang Pan; Li Chen; Shujun Liu; Xiaojuan Yang; Jian-Xin Gao; Robert J Lee
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

10.  Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities.

Authors:  Ritu Shrestha; Mahmoud Elsabahy; Stephanie Florez-Malaver; Sandani Samarajeewa; Karen L Wooley
Journal:  Biomaterials       Date:  2012-08-16       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.